Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 5
2004 4
2006 3
2007 2
2008 7
2009 3
2010 8
2011 9
2012 12
2013 11
2014 4
2016 6
2017 5
2018 10
2019 17
2020 20
2021 24
2022 15
2023 31
2024 31
2025 19
2026 18

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Results by year

Filters applied: . Clear all
Page 1
A Durability Index for Atopic Dermatitis: Indirect Comparison of Lebrikizumab, Dupilumab, and Tralokinumab in Maintaining Efficacy Under Variable Treatment Adherence.
Silverberg JI, Irvine AD, Foley P, Del Rosso J, Puig L, Stein Gold L, Kamata M, Wollenberg A, Hong HC, Chu CY, Binamer Y, Dossenbach M, Casillas M, Gallo G, Akmaz B, Rand K, Chovatiya R. Silverberg JI, et al. Among authors: wollenberg a. Dermatol Ther (Heidelb). 2026 Jun 17. doi: 10.1007/s13555-026-01791-1. Online ahead of print. Dermatol Ther (Heidelb). 2026. PMID: 42307887
Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis.
Wollenberg A, Silverberg JI, Legat FJ, Tauber M, Laquer VT, Armstrong AW, Pink AE, Naldi L, Pulka G, Zdybski J, Tsianakas A, Diaz J, Svarca I, Beecker J, Balakirski G, Pauser S, Ulianov L, Ryzhkova A, Machu JL, Piketty C. Wollenberg A, et al. Acta Derm Venereol. 2026 Jun 10;106:0085. doi: 10.2340/actadv.v106.adv-2025-0085. Acta Derm Venereol. 2026. PMID: 42272192 Free PMC article. Clinical Trial.
Correction to: Real-World Evidence of Effectiveness and Safety of Abrocitinib, Baricitinib and Upadacitinib in Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Rønnstad ATM, Isufi D, Bunick CG, Chovatiya R, Nielsen ML, Alinaghi F, Thomsen SF, Vestergaard C, Wollenberg A, Egeberg A, Thyssen JP, Loft N. Rønnstad ATM, et al. Among authors: wollenberg a. Am J Clin Dermatol. 2026 May 5. doi: 10.1007/s40257-026-01025-2. Online ahead of print. Am J Clin Dermatol. 2026. PMID: 42084698 No abstract available.
Clinical Laboratory Parameters in Adolescents with Moderate-to-Severe Atopic Dermatitis Treated with Tralokinumab Up to Week 52 in the Phase 3 ECZTRA 6 Trial.
Paller AS, Cork MJ, Hong HC, Soong W, Schneider SKR, Lo H, Vinther F, Thøgersen P, Wollenberg A. Paller AS, et al. Among authors: wollenberg a. Dermatol Ther (Heidelb). 2026 Jun;16(6):3037-3048. doi: 10.1007/s13555-026-01745-7. Epub 2026 Apr 25. Dermatol Ther (Heidelb). 2026. PMID: 42033591 Free PMC article.
The definition of response and inadequate response to topical corticosteroid treatment in atopic dermatitis and related skin inflammatory diseases: A GA2LEN ADCARE statement paper.
Zuberbier T, Abuzakouk M, Angelova Fischer I, Arruda LK, Augustin M, Beck L, Bernstein J, Bindslev-Jensen C, Bertolín-Colilla M, Bangert C, Calderón-Llosa O, Canonica GW, Roldan-Castor MA, Casis-Hao RJ, Cherrez-Ojeda I, Choo KJL, Chularojanamontri L, Cork MJ, Craig TJ, Criado PR, Custovic A, Çetinarslan T, Çalıcıoğlu F, de Bruin-Weller M, Douladiris N, Ensina LF, Erdem Öztürk Y, Ertaş R, Ferrucci SM, Rosário Filho N, Flohr C, Fluhr J, Fomina D, Gregoriou S, Gotua M, Giménez-Arnau AM, Hoetzenecker W, Jack C, Criado RFJ, Katoh N, Katoulis A, Kökçü Karadağ Şİ, Larenas-Linnemann D, Lee HY, Lima H, Mansour E, Mortz CG, Morelo Rocha Felix M, Morris V, Moschione Castro A, Mota Veloso Bruscky D, Mukhina O, Nguyen DV, Nosbaum A, Ozceker D, Özkaya E, Oztas Kara R, Parisi CAS, Peter J, Puig L, Ramon GD, Rincón-Pérez C, Sahiner UM, Schmid-Grendelmeier P, Serra-Baldrich E, Sevimli Dikicier B, Smith CH, Staubach P, Stevanovic K, Su Kucuk O, Teovska Mitrevska N, Thaci D, Torres MJ, Torres T, Trócoli Zanetti ME, Tuchinda P, Vadasz Z, Vakirlis E, Vieira Duarte G, Virtanen H, Werfel T, Wollenberg A, Worm M, Yew YW, Pereira MP. Zuberbier T, et al. Among authors: wollenberg a. World Allergy Organ J. 2026 Apr 15;19(5):101380. doi: 10.1016/j.waojou.2026.101380. eCollection 2026 May. World Allergy Organ J. 2026. PMID: 42028244 Free PMC article.
Long-Term Dupilumab Treatment Is Not Associated with an Increased Overall Risk of Infections in Adults with Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label 5-Year Extension Study.
Beck LA, Simpson EL, Thaçi D, de Bruin-Weller M, Deleuran M, Kataoka Y, Blauvelt A, Wollenberg A, Eichenfield LF, Khokhar FA, Coleman A, Van Spall M, Ma Y, Avetisova E, Zhang A, Nguyen TV. Beck LA, et al. Among authors: wollenberg a. Adv Ther. 2026 Apr 18. doi: 10.1007/s12325-026-03582-8. Online ahead of print. Adv Ther. 2026. PMID: 41999446
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.
Blauvelt A, Hong HC, Katoh N, Langley RG, Laquer V, Lesiak A, Peris K, Seneschal J, Silvestre JF, Warren RB, Wollenberg A, Zirwas M, Bennike NH, Safavimanesh F, Tindberg AM, Reich K. Blauvelt A, et al. Among authors: wollenberg a. Dermatol Ther (Heidelb). 2026 Apr;16(4):2001-2018. doi: 10.1007/s13555-026-01656-7. Epub 2026 Feb 5. Dermatol Ther (Heidelb). 2026. PMID: 41642555 Free PMC article.
238 results